FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to haematology, cardiology and endocrinology, and concerns correction of blood microvesicle level in arterial hypertension with impaired glucose tolerance. That is ensured by integrated treatment including graduated physical exercises, and introduction of Fosinopril in a dose 10 mg once in the morning and pioglitazone in a dose 30 mg once in the morning. Therapeutic course is at least 7 weeks.
EFFECT: complex of drug-free modalities and specific pharmacological preparations combined with empirically specified time of treatment provides maintained optimum microvesicle level that in turn allows considerably reducing risk of thrombotic complications in given group of patients.
1 ex
